IOVA Posts Narrower-Than-Expected Q3 Loss, Amtagvi Sales Drive Top line

Iovance Biotherapeutics, Inc. (IOVA) incurred a third-quarter 2024 loss of 28 cents per share, narrower than the Zacks Consensus Estimate of a loss of 31 cents. In the year-ago quarter, the company reported a loss of 46 cents.During the quarter, the company generated total revenues of $58.6 million, entirely from the product sales of its two marketed drugs. The reported sales beat the Zacks Consensus Estimate of$53.5 million. In the year-ago quarter, Iovance recorded total revenues of $0.5 million.More on ...